newsfilter
← Latest News
GlobeNewswire·

FDA Grants Breakthrough Device Designation to Freenome’s Blood-Based SimpleScreen™ Lung Cancer Screening Test

BRISBANE, Calif., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Freenome, Inc. (NASDAQ:FRNM), an early cancer detection company developing blood-based screening tests, today announced that the U.S. Food and Drug Administration